Co-Authors
This is a "connection" page, showing publications co-authored by GENGWEN TIAN and LEONID METELITSA.
Connection Strength
3.539
-
PRDM1 is a key regulator of the natural killer T-cell central memory program and effector function. Cancer Immunol Res. 2025 Jan 16.
Score: 0.993
-
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016 06 01; 126(6):2341-55.
Score: 0.544
-
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. J Immunother Cancer. 2025 Jan 11; 13(1).
Score: 0.248
-
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2024 Apr; 30(4):1210.
Score: 0.235
-
Refining chimeric antigen receptors via barcoded protein domain combination pooled screening. Mol Ther. 2023 11 01; 31(11):3210-3224.
Score: 0.226
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388.
Score: 0.221
-
Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-a triggers tumorigenic inflammation in neuroblastoma. J Immunother Cancer. 2023 03; 11(3).
Score: 0.218
-
Natural killer T cells and other innate-like T?lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood. 2023 02 23; 141(8):869-876.
Score: 0.218
-
LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells. Cancer Immunol Res. 2023 02 03; 11(2):171-183.
Score: 0.217
-
IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol. 2018 10 01; 201(7):2141-2153.
Score: 0.159
-
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014 Oct 30; 124(18):2824-33.
Score: 0.120
-
Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clin Immunol. 2013 Oct; 149(1):55-64.
Score: 0.111
-
Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system. Cancer Res. 2014 Nov 01; 74(21):6260-70.
Score: 0.030